Reeve Bryce B, McFatrich Molly, Pinheiro Laura C, Weaver Meaghann S, Sung Lillian, Withycombe Janice S, Baker Justin N, Mack Jennifer W, Waldron Mia K, Gibson Deborah, Tomlinson Deborah, Freyer David R, Mowbray Catriona, Jacobs Shana, Palma Diana, Martens Christa E, Gold Stuart H, Jackson Kathryn D, Hinds Pamela S
Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina.
Department of Health Policy and Management, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, North Carolina.
Pediatr Blood Cancer. 2017 Mar;64(3). doi: 10.1002/pbc.26261. Epub 2016 Sep 21.
BACKGROUND: Adverse event (AE) reporting in oncology trials is required, but current practice does not directly integrate the child's voice. The Pediatric Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) is being developed to assess symptomatic AEs via child/adolescent self-report or proxy-report. This qualitative study evaluates the child's/adolescent's understanding and ability to provide valid responses to the PRO-CTCAE to inform questionnaire refinements and confirm content validity. PROCEDURE: From seven pediatric research hospitals, children/adolescents ages 7-15 years who were diagnosed with cancer and receiving treatment were eligible, along with their parent-proxies. The Pediatric PRO-CTCAE includes 130 questions that assess 62 symptomatic AEs capturing symptom frequency, severity, interference, or presence. Cognitive interviews with retrospective probing were completed with children in the age groups of 7-8, 9-12, and 13-15 years. The children/adolescents and proxies were interviewed independently. RESULTS: Two rounds of interviews involved 81 children and adolescents and 74 parent-proxies. Fifteen of the 62 AE terms were revised after Round 1, including refinements to the questions assessing symptom severity. Most participants rated the PRO-CTCAE AE items as "very easy" or "somewhat easy" and were able to read, understand, and provide valid responses to questions. A few AE items assessing rare events were challenging to understand. CONCLUSIONS: The Pediatric and Proxy PRO-CTCAE performed well among children and adolescents and their proxies, supporting its content validity. Data from PRO-CTCAE may improve symptomatic AE reporting in clinical trials and enhance the quality of care that children receive.
J Pain Symptom Manage. 2025-5
J Pain Symptom Manage. 2025-4
J Adolesc Young Adult Oncol. 2025-4
J Adolesc Young Adult Oncol. 2025-4
JAMA Netw Open. 2024-5-1
Pediatr Blood Cancer. 2024-1
Lancet Oncol. 2013-2-20
J Neurosci. 2010-7-14